Becton Dickinson (NYSE:BDX) said today that it has stopped selling a point-of-care test touted as being able to detect antibodies to COVID-19 in as little as 15 minutes. The test, by BioMedomics, was one of about 100 serological tests that the FDA allowed manufacturers to sell beginning March 26, 2020, if the companies self-validated their accuracy. […]
